-

11:14:45 AM

Latest PRVB Stock Market News

PRVB - Provention Bio Inc

06/02/21 7:05 AM

Nasdaq : PRVB

Provention Bio Announces the Grant of Inducement Awards

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to two new employees to purchase an aggregate of

RHEA-AI

very positive

06/01/21 7:05 AM

Nasdaq : PRVB

Provention Bio to Present at the Jefferies Virtual Healthcare Conference

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced management will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 10:30

RHEA-AI

neutral

05/27/21 9:45 PM

Nasdaq : PRVB

FDA Advisory Committee Votes in Favor of the Benefits of Teplizumab Outweighing the Risks in Support of Approval to Delay Clinical Type 1 Diabetes (T1D)

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug

RHEA-AI

neutral

05/27/21 7:05 AM

Nasdaq : PRVB

Provention Bio Stock Trading Halted Today

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that Nasdaq has halted trading of the Company's common stock.The U.S. Food and Drug Administration (FDA)

RHEA-AI

neutral

05/25/21 9:30 AM

Nasdaq : PRVB

Provention Bio Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Teplizumab

Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced today that the U.S. Food and Drug Administration (FDA) posted briefing documents for the May 27, 2021

RHEA-AI

neutral

05/06/21 7:00 AM

Nasdaq : PRVB

Provention Bio Reports First Quarter 2021 Financial Results and Provides Business Update

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results and provided a business update for the first quarter ended March 31, 2021."The first

RHEA-AI

neutral

05/03/21 5:00 PM

Nasdaq : PRVB

Provention Bio Announces the Grant of Inducement Awards

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to 22 new employees to purchase an aggregate of

RHEA-AI

very positive

04/29/21 4:00 PM

Nasdaq : PRVB

Provention Bio to Report First Quarter 2021 Financial Results on May 6, 2021

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its first quarter 2021 financial results on Thursday, May 6, 2021, before the opening

RHEA-AI

neutral

04/27/21 4:00 PM

Nasdaq : PRVB

Provention Bio Provides Additional Regulatory Update on Biologics License Application for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals

Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the Company took part in an informal meeting with the U.S. Food and Drug Administration (FDA) on April

RHEA-AI

neutral

04/08/21 4:01 PM

Nasdaq : PRVB

Provention Bio Provides Regulatory Update on Biologics License Application for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the Company received a notification on April 2, 2021 from the U.S. Food and Drug Administration

RHEA-AI

neutral

PRVB Data

industryMedicinal and Botanical Manufacturing
websitewww.proventionbio.com
ceoAshleigh Palmer
security nameProvention Bio Inc
issue typecs
sectorManufacturing
sic code2834
employees
tagsHealth Technology,Pharmaceuticals: Major,Manufacturing,Medicinal and Botanical Manufacturing
address55 Broad Street, 2Nd Floor
address2
stateNew Jersey
cityRed Bank
zip07701
countryUS
phone19084289136

PRVB Description:

Provention Bio, Inc. is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Biologics License Application (BLA) for teplizumab, its lead investigational drug candidate, for the delay or prevention of clinical type 1 diabetes in at-risk individuals, has been filed by the U.S. Food and Drug Administration (FDA). The Company's pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus.